期刊文献+

芪龙糖肾汤治疗糖尿病肾病的临床观察 被引量:1

Clinical Observation on Qilong Tangshen Decoction in Treating Diabetic Nephropathy
在线阅读 下载PDF
导出
摘要 目的观察芪龙糖肾汤应用于中期糖尿病肾病患者临床治疗中的效果。方法选取2015年3月—2017年3月在沈阳市中医院肾病科门诊及病房收治的中期糖尿病肾病患者132例,随机分为对照组及治疗组各66例,分别给予西药ACEI/ARB类口服和加用芪龙糖肾汤治疗。结果尿微量白蛋白、24 h尿蛋白定量、空腹血糖、餐后2 h血糖、血浆总胆固醇、甘油三酯等相关指标,治疗组患者均明显优于对照组(P<0.05);治疗总有效率,治疗组明显高于对照组(P<0.05)。结论芪龙糖肾汤应用于中期糖尿病肾病患者临床治疗的效果十分理想,值得临床推广运用。 Objective To observe the clinical effect of Qilong Tangshen decoction in treating the early and middle stage diabetic nephropathy. Methods 132 patients with diabetic nephropathy from March 2015 to March 2017 in the nephropathy department of Shenyang hospital of traditional Chinese medicine were chosen for this study. These patients were randomly divided into the control group of 66 cases and the treatment group of 66 cases in order to compare the treatment effect from medicine containing ACEI/ARB and Qilong Tangshen decoction. Results In terms of the level of urine microalbumin, 24-hour urinary protein, fasting blood-glucose(FBG), 2-hour postprandial blood glucose(PBG), serum total cholesterol and triglyceride, the clinical effect of the treatment group were dramatically better than the other group. The total effective rate of the treatment group(92.42 %) was obviously higher than that of the control group( 72.73%). Comparing with the control group( P〈0.05), these comparative data had statistical significance. Conclusion Qilong Tangshen decoction in the treatment of the early and middle stage diabetic nephropathy has salient effect, and is worth popularizing in the clinical treatment.
作者 申林
出处 《中国中医药现代远程教育》 2017年第19期62-63,68,共3页 Chinese Medicine Modern Distance Education of China
关键词 芪龙糖肾汤 糖尿病 肾病 消渴 水肿 Qilong Tangshen decoction diabetes nephropathy consumptive thirst edema
  • 相关文献

参考文献5

二级参考文献42

  • 1马艳春,周波,张立净,孙许涛,姚远,宋立群,肖洪彬.中药治疗糖尿病肾病的作用机制研究进展[J].中医药学报,2009,37(6):105-108. 被引量:40
  • 2董柯,陈香美,汤力.水蛭对系膜增殖性肾炎蛋白尿、脂质代谢及凝血机制的影响[J].中华内科杂志,1995,34(4):250-252. 被引量:58
  • 3王东,陈霞,李连喜,杨玲.2型糖尿病肾病患者血浆NO,ET,TXA_2,PGI_2的临床分析[J].江苏大学学报(医学版),2006,16(6):513-515. 被引量:5
  • 4Ravera M, Re M, Weiss U,et al. Emerging therapeutic strategies in diabetic nephropathy [J].J Nephrol, 2007 ; 20 ( 6 ) : S23 (Review).
  • 5Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure inpatients with type 2 diabetes mellitus and overt nephropathy[J]. Am J Kidney Dis,2005 ;45 (2) :281.
  • 6Keane WF,Brenner BM, de Zeeuw D,et al. The risk of developing endstage renal disease inpatients with type 2 diabetes and nephropathy:the RENAAL study[J]. Kidney Int,2003 ;63 (4) :1499.
  • 7Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy[J]. Drugs,2007 ;67 ( 18 ) :2681.
  • 8郑筱萸.中药新药治疗消渴病(糖尿病)的临床研究指导原则[M].北京:中国中医药科技出版社,2002,232-234.
  • 9Report of a WHO consultation.Definition,diagnosis and classification of diabetesmellitus and its complication[S] Geneva:World Health Organization,1999.53.
  • 10潘长玉.糖尿病学[M].第14版.北京:人民卫生出版社,2007:693-709.

共引文献19

同被引文献2

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部